أخبار

TIF Issues Position Statement in Honour of the World Blood Donor Day 2020

TIF Issues Position Statement in Honour of the World Blood Donor Day 2020

There is one thing that definitely makes us heroes: giving blood.  It is a life-saving gesture that any of us in good health should very seriously consider making. Every couple…
JUST LANDED: The ”Prevention of Inherited Diseases – The Example of β-Thalassaemi” Educational Brochure by TIF

JUST LANDED: The ”Prevention of Inherited Diseases – The Example of β-Thalassaemi” Educational Brochure by TIF

Prevention is the only measure that can drastically reduce the incidencies of severe haemoglobin disorders, such as β-thalassaemia. It is also what allowed countries like Greece, Italy and Cyprus to go from…
WORLD BLOOD DONOR DAY 2020: Give blood and make the world a healthier place

WORLD BLOOD DONOR DAY 2020: Give blood and make the world a healthier place

On 14 June 2020 WHO and all countries worldwide will celebrate World Blood Donor Day!   The campaign theme for this year’s World Blood Donor Day is “Safe blood saves…
”Why I decided to increase awareness about thalassaemia in Singapore”: The story of Jensen Chan

”Why I decided to increase awareness about thalassaemia in Singapore”: The story of Jensen Chan

”I was shocked at the huge discrepancy between how common thalassaemia is and how few people actually know about it.” Jensen Chan, a University student from Singapore, explains how his…
FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets

FDA Approves New Formulation for Ferriprox (Deferiprone) Twice-a-Day Tablets

Chiesi Global Rare Diseases, a business unit of Chiesi Farmaceutici S.p.A., today announced that the U.S. Food and Drug Administration (FDA) has approved Ferriprox® (deferiprone) twice-a-day tablets for the treatment…
TIF ITD2020 Webinar: The Patients’ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia

TIF ITD2020 Webinar: The Patients’ Perspective on the Accessibility & Affordability of Novel Therapies for Thalassaemia

9 patients with thalassaemia, members of TIF’s Patient Advocacy Group for Thalassaemia and Sickle Cell Disease (T-PAG), are discussing with the Thalassaemia International Federation the accessibility and affordability of the…
COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patient Advocates from Europe

COVID-19 & Haemoglobin Disorders: A TIF Webinar with Patient Advocates from Europe

Patient Advocates from Greece, Germany, the UK, the Netherlands, Romania and other countries of the WHO European Region exchange thoughts and opinions with TIF about the daunting challenges and concerns…
COVID-19 & Haemoglobin Disorders: The Cyprus Webinar

COVID-19 & Haemoglobin Disorders: The Cyprus Webinar

In the context of TIF’s intensive efforts for the accurate and timely information of individuals with thalassaemia and sickle cell disease (SCD) in relation to the COVID-19 pandemic, the Federation…
زر الذهاب إلى الأعلى
إغلاق
إغلاق